Cardiac magnetic resonance using late gadolinium enhancement and atrial T1 mapping predicts poor outcome in patients with atrial fibrillation after catheter ablation therapy
Abstract To determine the pre-procedural value of different fibrotic biomarkers and comprehensive cardiac magnetic resonance (CMR) for the prediction of poor response to ablation therapy in patients with atrial fibrillation (AF). Left atrial (LA) late gadolinium enhancement (LGE) and native LA T1 re...
Main Authors: | , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2018-09-01
|
Series: | Scientific Reports |
Subjects: | |
Online Access: | https://doi.org/10.1038/s41598-018-31916-2 |
id |
doaj-a791bc9426054598af890b1907253b3b |
---|---|
record_format |
Article |
spelling |
doaj-a791bc9426054598af890b1907253b3b2020-12-08T05:02:35ZengNature Publishing GroupScientific Reports2045-23222018-09-01811910.1038/s41598-018-31916-2Cardiac magnetic resonance using late gadolinium enhancement and atrial T1 mapping predicts poor outcome in patients with atrial fibrillation after catheter ablation therapyJulian A. Luetkens0Anne C. Wolpers1Thomas Beiert2Daniel Kuetting3Darius Dabir4Rami Homsi5Hendrik Meendermann6Natalie Abou Dayé7Vincent Knappe8Morten Karsdal9Signe H. Nielsen10Federica Genovese11Florian Stöckigt12Markus Linhart13Daniel Thomas14Georg Nickenig15Hans H. Schild16Jan W. Schrickel17René P. Andrié18Department of Radiology, University Hospital Bonn, Rheinische Friedrich-Wilhelms UniversityDepartment of Internal Medicine II, University Hospital Bonn, Rheinische Friedrich-Wilhelms UniversityDepartment of Internal Medicine II, University Hospital Bonn, Rheinische Friedrich-Wilhelms UniversityDepartment of Radiology, University Hospital Bonn, Rheinische Friedrich-Wilhelms UniversityDepartment of Radiology, University Hospital Bonn, Rheinische Friedrich-Wilhelms UniversityDepartment of Radiology, University Hospital Bonn, Rheinische Friedrich-Wilhelms UniversityDepartment of Internal Medicine II, University Hospital Bonn, Rheinische Friedrich-Wilhelms UniversityDepartment of Internal Medicine II, University Hospital Bonn, Rheinische Friedrich-Wilhelms UniversityDepartment of Internal Medicine II, University Hospital Bonn, Rheinische Friedrich-Wilhelms UniversityFibrosis Biology and Biomarkers, Nordic BioscienceFibrosis Biology and Biomarkers, Nordic BioscienceFibrosis Biology and Biomarkers, Nordic BioscienceDepartment of Internal Medicine II, University Hospital Bonn, Rheinische Friedrich-Wilhelms UniversityDepartment of Internal Medicine II, University Hospital Bonn, Rheinische Friedrich-Wilhelms UniversityDepartment of Radiology, University Hospital Bonn, Rheinische Friedrich-Wilhelms UniversityDepartment of Internal Medicine II, University Hospital Bonn, Rheinische Friedrich-Wilhelms UniversityDepartment of Radiology, University Hospital Bonn, Rheinische Friedrich-Wilhelms UniversityDepartment of Internal Medicine II, University Hospital Bonn, Rheinische Friedrich-Wilhelms UniversityDepartment of Internal Medicine II, University Hospital Bonn, Rheinische Friedrich-Wilhelms UniversityAbstract To determine the pre-procedural value of different fibrotic biomarkers and comprehensive cardiac magnetic resonance (CMR) for the prediction of poor response to ablation therapy in patients with atrial fibrillation (AF). Left atrial (LA) late gadolinium enhancement (LGE) and native LA T1 relaxation times were assessed using CMR. Plasma levels of relaxin, myeloperoxidase and serum levels of matrix metalloproteinase (MMP)-mediated cardiac specific titin fragmentation and MMP-mediated type IV collagen degradation were obtained. Poor outcome was defined by the recurrence of AF during 1-year follow-up. 61 patients were included in final analysis. Twenty (32.8%) patients had recurrence of AF. Patients with a recurrence of AF had a higher percentage of LA LGE (26.7 ± 12.5% vs. 17.0 ± 7.7%; P < 0.001), higher LA T1 relaxation times (856.7 ± 112.2 ms vs. 746.8 ± 91.0 ms; P < 0.001) and higher plasma levels of relaxin (0.69 ± 1.34 pg/ml vs. 0.37 ± 0.88 pg/ml; P = 0.035). In the multivariate Cox regression analysis, poor ablation outcome was best predicted by advanced LGE stage (hazard ratio (HR):5.487; P = 0.001) and T1 relaxation times (HR:1.007; P = 0.001). Pre-procedural CMR is a valuable tool for prediction of poor response to catheter ablation therapy in patients with AF. It offers various imaging techniques for outcome prediction and might be valuable for a better patient selection prior to ablation therapy.https://doi.org/10.1038/s41598-018-31916-2Catheter Ablation TherapyLate Gadolinium Enhancement (LGE)RelaxinFibrotic BiomarkersLeft Atrial (LA) |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Julian A. Luetkens Anne C. Wolpers Thomas Beiert Daniel Kuetting Darius Dabir Rami Homsi Hendrik Meendermann Natalie Abou Dayé Vincent Knappe Morten Karsdal Signe H. Nielsen Federica Genovese Florian Stöckigt Markus Linhart Daniel Thomas Georg Nickenig Hans H. Schild Jan W. Schrickel René P. Andrié |
spellingShingle |
Julian A. Luetkens Anne C. Wolpers Thomas Beiert Daniel Kuetting Darius Dabir Rami Homsi Hendrik Meendermann Natalie Abou Dayé Vincent Knappe Morten Karsdal Signe H. Nielsen Federica Genovese Florian Stöckigt Markus Linhart Daniel Thomas Georg Nickenig Hans H. Schild Jan W. Schrickel René P. Andrié Cardiac magnetic resonance using late gadolinium enhancement and atrial T1 mapping predicts poor outcome in patients with atrial fibrillation after catheter ablation therapy Scientific Reports Catheter Ablation Therapy Late Gadolinium Enhancement (LGE) Relaxin Fibrotic Biomarkers Left Atrial (LA) |
author_facet |
Julian A. Luetkens Anne C. Wolpers Thomas Beiert Daniel Kuetting Darius Dabir Rami Homsi Hendrik Meendermann Natalie Abou Dayé Vincent Knappe Morten Karsdal Signe H. Nielsen Federica Genovese Florian Stöckigt Markus Linhart Daniel Thomas Georg Nickenig Hans H. Schild Jan W. Schrickel René P. Andrié |
author_sort |
Julian A. Luetkens |
title |
Cardiac magnetic resonance using late gadolinium enhancement and atrial T1 mapping predicts poor outcome in patients with atrial fibrillation after catheter ablation therapy |
title_short |
Cardiac magnetic resonance using late gadolinium enhancement and atrial T1 mapping predicts poor outcome in patients with atrial fibrillation after catheter ablation therapy |
title_full |
Cardiac magnetic resonance using late gadolinium enhancement and atrial T1 mapping predicts poor outcome in patients with atrial fibrillation after catheter ablation therapy |
title_fullStr |
Cardiac magnetic resonance using late gadolinium enhancement and atrial T1 mapping predicts poor outcome in patients with atrial fibrillation after catheter ablation therapy |
title_full_unstemmed |
Cardiac magnetic resonance using late gadolinium enhancement and atrial T1 mapping predicts poor outcome in patients with atrial fibrillation after catheter ablation therapy |
title_sort |
cardiac magnetic resonance using late gadolinium enhancement and atrial t1 mapping predicts poor outcome in patients with atrial fibrillation after catheter ablation therapy |
publisher |
Nature Publishing Group |
series |
Scientific Reports |
issn |
2045-2322 |
publishDate |
2018-09-01 |
description |
Abstract To determine the pre-procedural value of different fibrotic biomarkers and comprehensive cardiac magnetic resonance (CMR) for the prediction of poor response to ablation therapy in patients with atrial fibrillation (AF). Left atrial (LA) late gadolinium enhancement (LGE) and native LA T1 relaxation times were assessed using CMR. Plasma levels of relaxin, myeloperoxidase and serum levels of matrix metalloproteinase (MMP)-mediated cardiac specific titin fragmentation and MMP-mediated type IV collagen degradation were obtained. Poor outcome was defined by the recurrence of AF during 1-year follow-up. 61 patients were included in final analysis. Twenty (32.8%) patients had recurrence of AF. Patients with a recurrence of AF had a higher percentage of LA LGE (26.7 ± 12.5% vs. 17.0 ± 7.7%; P < 0.001), higher LA T1 relaxation times (856.7 ± 112.2 ms vs. 746.8 ± 91.0 ms; P < 0.001) and higher plasma levels of relaxin (0.69 ± 1.34 pg/ml vs. 0.37 ± 0.88 pg/ml; P = 0.035). In the multivariate Cox regression analysis, poor ablation outcome was best predicted by advanced LGE stage (hazard ratio (HR):5.487; P = 0.001) and T1 relaxation times (HR:1.007; P = 0.001). Pre-procedural CMR is a valuable tool for prediction of poor response to catheter ablation therapy in patients with AF. It offers various imaging techniques for outcome prediction and might be valuable for a better patient selection prior to ablation therapy. |
topic |
Catheter Ablation Therapy Late Gadolinium Enhancement (LGE) Relaxin Fibrotic Biomarkers Left Atrial (LA) |
url |
https://doi.org/10.1038/s41598-018-31916-2 |
work_keys_str_mv |
AT julianaluetkens cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy AT annecwolpers cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy AT thomasbeiert cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy AT danielkuetting cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy AT dariusdabir cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy AT ramihomsi cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy AT hendrikmeendermann cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy AT natalieaboudaye cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy AT vincentknappe cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy AT mortenkarsdal cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy AT signehnielsen cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy AT federicagenovese cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy AT florianstockigt cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy AT markuslinhart cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy AT danielthomas cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy AT georgnickenig cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy AT hanshschild cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy AT janwschrickel cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy AT renepandrie cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy |
_version_ |
1724391911951695872 |